Next, we evaluated the correlation between the IRGPs signature and clinical characteristics (age, gender, smoking, EGFR mutation, KARS mutation, radiotherapy, chemotherapy, TNM stage, tumor size, lymph node metastasis, and distant metastasis). Here, KARS1 is linked to metastatic malignant neoplasm in the lymph nodes.